A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer

Soukup, 2020, Risk stratification tools and prognostic models in non-muscle invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Eur Urol Focus, 6, 479, 10.1016/j.euf.2018.11.005 Tang, 2015, Management of carcinoma in situ of the bladder: best practice and recent developments, Ther Adv Urol, 7, 351, 10.1177/1756287215599694 Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. https://www.fda.gov/media/101468/download. Tan, 2015, Complications of radical cystectomy and orthotopic reconstruction, Adv Urol, 2015, 323157, 10.1155/2015/323157 Balar, 2021, Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study, Lancet Oncol, 22, 919, 10.1016/S1470-2045(21)00147-9 U.S. Food and Drug Administration. FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer. D’Hallewin, 1995, Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder, Urology, 45, 763, 10.1016/S0090-4295(99)80080-6 Agostinis, 2011, Photodynamic therapy of cancer: an update, CA Cancer J Clin, 61, 250, 10.3322/caac.20114 Kwiatkowski, 2018, Photodynamic therapy – mechanisms, photosensitizers and combinations, Biomed Pharmacother, 106, 1098, 10.1016/j.biopha.2018.07.049 Hansen, 2014, Phase 1 trial design: is 3+3 the best?, Cancer Control, 21, 200, 10.1177/107327481402100304 Alzeibak, 2021, Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future [published correction appears in J Immunother Cancer 2021 Oct; 9(10):], J Immunother Cancer, 9, e001926, 10.1136/jitc-2020-001926 Meng, 2019, Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations, Adv Mater, 31, e1900927, 10.1002/adma.201900927 National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Cancer Therapy Evaluation Program (CTEP). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Wojciech, 2014, Searching for an optimal AUC estimation method: a never-ending task?, J Pharmacokinet Pharmacodyn, 41, 655, 10.1007/s10928-014-9392-y Nseyo UO. Sequential whole bladder photodynamic therapy (WBPDT) in the management of superficial bladder cancer. Clinicaltrials.gov identifier: NCT00322699. https://clinicaltrials.gov/ct2/show/record/NCT00322699?view=record. Mejia MC, Nseyo UO. Safety of three sequential whole bladder photodynamic therapy (WBPDT) treatments in the management of resistant bladder cancer. Photonic Therapeutics and Diagnostics V; 71611P. 2009. Progress in Biomedical Optics and Imaging—Proceedings of SPIE. 7161. Kasper, 2016, A ruthenium(II) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy, Photochem Photobiol Sci, 15, 481, 10.1039/C5PP00450K Monro, 2019, Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433, Chem Rev, 119, 797, 10.1021/acs.chemrev.8b00211 Shi, 2015, Ru(II) dyads derived from α-oligothiophenes: a new class of potent and versatile photosensitizers for PDT, Coord Chem Rev, 282–3, 127, 10.1016/j.ccr.2014.04.012 Alberto, 2016, Theoretical exploration of type I/type II dual photoreactivity of promising Ru(II) dyads for PDT approach, Inorg Chem, 55, 11185, 10.1021/acs.inorgchem.6b01782 Srikrishna, 2009, Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer, Neoplasia, 11, 615, 10.1593/neo.09284 Boorjian, 2021, Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial, Lancet Oncol, 22, 107, 10.1016/S1470-2045(20)30540-4 Steinberg, 2020, Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer, J Urol, 203, 902, 10.1097/JU.0000000000000688